Corvus Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary

Corvus Pharmaceuticals (NASDAQ: CRVS) announced its participation in two upcoming investor conferences. The company will present at the HC Wainwright 22nd Annual Investment Conference on September 14, 2020, at 4:00 PM ET, and at the Cantor Virtual Healthcare Conference on September 17, 2020, at 4:40 PM ET. Both presentations will be available via webcast for 90 days on the Corvus website. Corvus is focused on developing innovative therapies for cancer and is currently advancing multiple clinical trials.

BURLINGAME, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the following investor conferences:

• HC Wainwright 22^nd Annual Investment Conference on September 14, 2020 at 4:00 pm ET
   
• Cantor Virtual Healthcare Conference on September 17, 2020 at 4:40 pm ET

A webcast of the presentations will be available live and for 90 days following the event. The webcast may be accessed via the investor relations section of the Corvus website.

About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus’ lead product candidates are ciforadenant (CPI-444), a small molecule inhibitor of the A2A receptor, and CPI-006, a humanized monoclonal antibody directed against CD73 that exhibits immunomodulatory activity and activation of immune cells. These product candidates are being studied in ongoing Phase 1b/2 and Phase 1/1b clinical trials in patients with a wide range of advanced solid tumors. Ciforadenant is being evaluated in a successive expansion cohort Phase 1b/2 trial examining its activity both as a single agent and in combination with an anti-PD-L1 antibody. CPI-006 is being evaluated in a multicenter Phase 1/1b clinical trial as a single agent, in combination with ciforadenant and pembrolizumab. The Company’s third cancer clinical program, CPI-818, an oral, small molecule drug that has been shown to selectively inhibit ITK, is in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. The Company is also evaluating CPI-006 as a treatment for COVID-19 patients.  For more information, visit www.corvuspharma.com.

INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
650-900-4522
LLea@corvuspharma.com

MEDIA CONTACT:
Sheryl Seapy
W2O pure
+1 213-262-9390
sseapy@purecommunications.com

 

FAQ

When is Corvus Pharmaceuticals presenting at the investor conferences?

Corvus Pharmaceuticals will present at the HC Wainwright 22nd Annual Investment Conference on September 14, 2020, at 4:00 PM ET, and at the Cantor Virtual Healthcare Conference on September 17, 2020, at 4:40 PM ET.

How can I watch the Corvus Pharmaceuticals conference presentations?

The presentations can be accessed via live webcast on the investor relations section of the Corvus Pharmaceuticals website, and will be available for 90 days following the events.

What is the focus of Corvus Pharmaceuticals' clinical trials?

Corvus Pharmaceuticals is conducting clinical trials focused on therapies for cancer, including candidates such as ciforadenant and CPI-006.

What are the key products being studied by Corvus Pharmaceuticals?

Corvus Pharmaceuticals' lead product candidates include ciforadenant, a small molecule inhibitor, and CPI-006, a humanized monoclonal antibody, both targeting advanced solid tumors.

Where can I find more information about Corvus Pharmaceuticals?

More information about Corvus Pharmaceuticals can be found on their official website at www.corvuspharma.com.